The gene therapy market size is poised to grow by $ 15.68 billion by 2030 from $ 3.59 Billion in 2022, exhibiting a CAGR of 20.2% during the forecast period 2022 to 2030.

Key Takeaway:

• By indication, the spinal muscular atrophy (SMA) segment has captured 42% revenue share in 2021.
• By vector type, the AAV segment accounted market share of around 44% in 2021.
• By gene type, the antigen gene segment has accounted highest revenue share in 2021.
• By application, the oncological disorders segment has accounted highest market share in 2021.
• The North America region hit revenue share of around 56%.

Get a Sample: https://www.precedenceresearch.com/sample/1462 

COVID-19 Impact

Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 100 countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the electric vehicle fuel cell market in 2020.

COVID-19 can affect the global economy in three main ways: by directly affecting production and demand, by creating supply chain and market disruption, and by its financial impact on firms and financial markets.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.

Major companies operating in this are

• Dimension Therapeutics Inc.
• Taxus Cardium Pharmaceuticals Group Inc.
• Epeius Biotechnologies Corp.
• Shanghai Sunway Biotech Co. Ltd
• Applied Genetic Technologies Corporation
• Bristol-Myers Squibb Company
• American Gene Technologies
• BioMarin Pharmaceuticals Inc.
• Gensight Biologics S.A.
• Sibinono GeneTech Co. Ltd

Market Segmentation

By Vector Type

• Viral Vectors
  • Retro Viral Vectors
  • Adeno-associated Virus Vectors
  • Other Viral Vectors
• Non-viral Vectors
  • Oligonucleotides
  • Other Non-viral Vectors

By Delivery Method

• In Vivo
• Ex Vivo

By Gene Type

• Antigen
• Cytokine
• Tumor Suppressor
• Suicide
• Deficiency
• Receptors
• Others

By Application

• Oncological Disorders
• Rare Diseases
• Cardiovascular Diseases
• Neurological Disorders
• Infectious Diseases
• Others

By Geography

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
• LATAM
• Rest of the World

Major highlights of Report:

• Figures related to sales volume, market remuneration, and segmental shares
• Featuring market dynamics
• Growth prospects and expansion graph
• PROCON study of direct & indirect sales channels
• Profiles of prominent traders, dealer, and distributors in the industry

Geographical landscape: North America, Europe, Asia-Pacific, South America, Middle East and Africa

• Industry forecasts based on region and at country level
• Data about sales volume recorded, industry share held, and profit margins amassed
• Overall remuneration and estimated growth rate for each regional market

Major Key Points Covered in Report:

Executive Summary: It includes key trends of the electric vehicle fuel cell market related to products, applications, and other crucial factors. It also provides analysis of the competitive landscape and CAGR and market size of the electric vehicle fuel cell market based on production and revenue.

Production and Consumption by Region: It covers all regional markets to which the research study relates. Prices and key players in addition to production and consumption in each regional market are discussed.

Key Players: Here, the report throws light on financial ratios, pricing structure, production cost, gross profit, sales volume, revenue, and gross margin of leading and prominent companies competing in the Electric vehicle fuel cell market.

Market Segments: This part of the report discusses product, application and other segments of the electric vehicle fuel cell market based on market share, CAGR, market size, and various other factors.

Research Methodology: This section discusses the research methodology and approach used to prepare the report. It covers data triangulation, market breakdown, market size estimation, and research design and/or programs.

TABLE OF CONTENT

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Gene Therapy Market 

5.1. COVID-19 Landscape: Gene Therapy Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Gene Therapy Market, By Vector

8.1. Gene Therapy Market, by Vector Type, 2021-2030

8.1.1. Viral Vector

8.1.1.1. Market Revenue and Forecast (2019-2030)

8.1.2. Non-viral Vector

8.1.2.1. Market Revenue and Forecast (2019-2030)

Chapter 9. Global Gene Therapy Market, By Application

9.1. Gene Therapy Market, by Application, 2021-2030

9.1.1. Oncological Disorders

9.1.1.1. Market Revenue and Forecast (2019-2030)

9.1.2. Rare Diseases

9.1.2.1. Market Revenue and Forecast (2019-2030)

9.1.3. Cardiovascular Diseases

9.1.3.1. Market Revenue and Forecast (2019-2030)

9.1.4. Neurological Disorders

9.1.4.1. Market Revenue and Forecast (2019-2030)

9.1.5. Infectious Diseases

9.1.5.1. Market Revenue and Forecast (2019-2030)

9.1.6. Others

9.1.6.1. Market Revenue and Forecast (2019-2030)

Chapter 10. Global Gene Therapy Market, By Gene 

10.1. Gene Therapy Market, by Gene, 2021-2030

10.1.1. Antigen

10.1.1.1. Market Revenue and Forecast (2019-2030)

10.1.2. Cytokine

10.1.2.1. Market Revenue and Forecast (2019-2030)

10.1.3. Tumor Suppressor

10.1.3.1. Market Revenue and Forecast (2019-2030)

10.1.4. Suicide

10.1.4.1. Market Revenue and Forecast (2019-2030)

10.1.5. Deficiency

10.1.5.1. Market Revenue and Forecast (2019-2030)

10.1.6. Receptors

10.1.6.1. Market Revenue and Forecast (2019-2030)

10.1.7. Others

10.1.7.1. Market Revenue and Forecast (2019-2030)

Chapter 11. Global Gene Therapy Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Forecast, by Vector (2019-2030)

11.1.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.3. Market Revenue and Forecast, by Gene (2019-2030)

11.1.4. U.S.

11.1.4.1. Market Revenue and Forecast, by Vector (2019-2030)

11.1.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.4.3. Market Revenue and Forecast, by Gene (2019-2030)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Forecast, by Vector (2019-2030)

11.1.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.1.5.3. Market Revenue and Forecast, by Gene (2019-2030)

11.2. Europe

11.2.1. Market Revenue and Forecast, by Vector (2019-2030)

11.2.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.3. Market Revenue and Forecast, by Gene (2019-2030)

11.2.4. UK

11.2.4.1. Market Revenue and Forecast, by Vector (2019-2030)

11.2.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.4.3. Market Revenue and Forecast, by Gene (2019-2030)

11.2.5. Germany

11.2.5.1. Market Revenue and Forecast, by Vector (2019-2030)

11.2.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.5.3. Market Revenue and Forecast, by Gene (2019-2030)

11.2.6. France

11.2.6.1. Market Revenue and Forecast, by Vector (2019-2030)

11.2.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.6.3. Market Revenue and Forecast, by Gene (2019-2030)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Forecast, by Vector (2019-2030)

11.2.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.2.7.3. Market Revenue and Forecast, by Gene (2019-2030)

11.3. APAC

11.3.1. Market Revenue and Forecast, by Vector (2019-2030)

11.3.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.3. Market Revenue and Forecast, by Gene (2019-2030)

11.3.4. India

11.3.4.1. Market Revenue and Forecast, by Vector (2019-2030)

11.3.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.4.3. Market Revenue and Forecast, by Gene (2019-2030)

11.3.5. China

11.3.5.1. Market Revenue and Forecast, by Vector (2019-2030)

11.3.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.5.3. Market Revenue and Forecast, by Gene (2019-2030)

11.3.6. Japan

11.3.6.1. Market Revenue and Forecast, by Vector (2019-2030)

11.3.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.6.3. Market Revenue and Forecast, by Gene (2019-2030)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Forecast, by Vector (2019-2030)

11.3.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.3.7.3. Market Revenue and Forecast, by Gene (2019-2030)

11.4. MEA

11.4.1. Market Revenue and Forecast, by Vector (2019-2030)

11.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.3. Market Revenue and Forecast, by Gene (2019-2030)

11.4.4. GCC

11.4.4.1. Market Revenue and Forecast, by Vector (2019-2030)

11.4.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.4.3. Market Revenue and Forecast, by Gene (2019-2030)

11.4.5. North Africa

11.4.5.1. Market Revenue and Forecast, by Vector (2019-2030)

11.4.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.5.3. Market Revenue and Forecast, by Gene (2019-2030)

11.4.6. South Africa

11.4.6.1. Market Revenue and Forecast, by Vector (2019-2030)

11.4.6.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.6.3. Market Revenue and Forecast, by Gene (2019-2030)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Forecast, by Vector (2019-2030)

11.4.7.2. Market Revenue and Forecast, by Application (2019-2030)

11.4.7.3. Market Revenue and Forecast, by Gene (2019-2030)

11.5. Latin America

11.5.1. Market Revenue and Forecast, by Vector (2019-2030)

11.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.3. Market Revenue and Forecast, by Gene (2019-2030)

11.5.4. Brazil

11.5.4.1. Market Revenue and Forecast, by Vector (2019-2030)

11.5.4.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.4.3. Market Revenue and Forecast, by Gene (2019-2030)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Forecast, by Vector (2019-2030)

11.5.5.2. Market Revenue and Forecast, by Application (2019-2030)

11.5.5.3. Market Revenue and Forecast, by Gene (2019-2030)

Chapter 12. Company Profiles

12.1. Dimension Therapeutics Inc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Taxus Cardium Pharmaceuticals Group Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Epeius Biotechnologies Corp.

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Shanghai Sunway Biotech Co. Ltd

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Applied Genetic Technologies Corporation

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bristol-Myers Squibb Company

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. American Gene Technologies

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. BioMarin Pharmaceuticals Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Gensight Biologics S.A.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Sibinono GeneTech Co. Ltd

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Thanks for reading you can also get individual chapter-wise sections or region-wise report versions such as North America, Europe, or the Asia Pacific.

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: [email protected]

Web: https://www.precedenceresearch.com

Blog: https://www.pharma-geek.com